Login to Your Account

NewCo News

MorphoSys Backs Dutch Firm Lanthio in $6M Series A Round

By Cormac Sheridan
Staff Writer

Wednesday, November 28, 2012
Lanthio Pharma BV found an influential backer for its peptide technology in the shape of antibody developer MorphoSys AG, which has participated in its €4.8 million (US$6.2 million) Series A round and which will help it to develop and commercialize its LanthioPep platform.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription